Division of Pulmonary Medicine, University Hospital Zurich, Zurich, Switzerland.
J Heart Lung Transplant. 2011 Jun;30(6):685-90. doi: 10.1016/j.healun.2011.01.707. Epub 2011 Mar 27.
Pandemic 2009 H1N1 influenza virus (H1N1) infection is considered harmful to lung transplant recipients (LTRs). Vaccination against this virus is recommended for LTRs, but little is known about associated benefits and risks. Our aim in this study is to document the safety and clinical effectiveness of the H1N1 vaccine in LTRs.
All LTRs received an informational letter on the H1N1 pandemic that included hygiene and vaccination recommendations. After completing a questionnaire, volunteering LTRs received Pandemrix (H1N1 2009 Monovalent AS03-Adjuvanted Vaccine; GSK). Adverse events (AEs) were documented at short-term follow-up visits and by telephone. Any flu-like symptoms were reported and a low threshold for performing nasal/pharyngeal swabs for virus detection was maintained.
Of 168 eligible LTRs (107 already vaccinated for 2009 seasonal influenza), 148 (88%) received at least one vaccination with the H1N1 vaccine and 115 received a second dose. After the first vaccination, 44% had no AEs. Six self-limiting, severe AEs occurred, and the remainder were minor to moderate, predominantly injection-site reactions. After the second vaccination, AEs were clearly less frequent. All AEs resolved completely. Documented H1N1 infection occurred in 2 of 148 vaccinated LTRs, in contrast to 5 infections in 20 non-vaccinated LTRs.
H1N1 vaccination is generally well tolerated with mild to moderate, predominantly local AEs in most LTRs and few self-limiting severe events. Clinical effectiveness is good.
大流行性 2009 年 H1N1 流感病毒（H1N1）感染被认为对肺移植受者（LTR）有害。建议 LTR 接种这种病毒疫苗，但对相关的益处和风险知之甚少。我们在这项研究中的目的是记录 H1N1 疫苗在 LTR 中的安全性和临床效果。
所有 LTR 都收到了一封关于大流行性 H1N1 的信息信，其中包括卫生和疫苗接种建议。在完成问卷调查后，自愿接种疫苗的 LTR 接种了 Panademrix（H1N1 2009 单价 AS03 佐剂疫苗；GSK）。在短期随访和电话随访中记录不良事件（AE）。报告任何流感样症状，并保持对病毒检测进行鼻/咽拭子的低阈值。
在 168 名符合条件的 LTR 中（107 名已接种 2009 年季节性流感疫苗），148 名（88%）至少接种了一剂 H1N1 疫苗，115 名接种了第二剂。第一次接种后，44%的人没有 AE。发生了 6 例自限性严重 AE，其余的是轻微至中度，主要是注射部位反应。第二次接种后，AE 明显减少。所有 AE 均完全缓解。在接种疫苗的 148 名 LTR 中，有 2 人发生了有记录的 H1N1 感染，而在 20 名未接种疫苗的 LTR 中，有 5 人发生了感染。
H1N1 疫苗接种在大多数 LTR 中通常耐受性良好，仅有轻度至中度、主要是局部的 AE，且很少发生自限性严重事件。临床效果良好。
